MARKET CATALYST · MEASUREMENT STARTING POINT
Oral and Generic Obesity Access
Oral and Generic Obesity Drugs: Can More People Stay on Paid Treatment at Lower Cost?
DATED BASELINE
Starting record
October 22, 2026
Oral and Generic Obesity Drugs: Can More People Stay on Paid Treatment at Lower Cost?
The two oral products launched in the United States in January and April 2026. Health Canada approved Apotex’s Sevmia on June 29, and the Medicare Bridge began July 1. Novo reports more than seven million Wegovy pill prescriptions in 2026 through its September presentation; Lilly reported $98 million of Foundayo revenue in Q2. These establish commercial activity and new access routes, not a count of persistent new patients.
Next review: October 29, 2026 · Terminal review: No fixed terminal date
The baseline records what was known at initiation. It does not assign a realized outcome or grade.
Keep product, country, currency, payer and cohort separate. Prescriptions are fills, not unique patients. No outcome grade is assigned; missing evidence is unknown, not a failed branch.
UNDER OBSERVATION
Foundayo product economics
- Starting evidence
- Q2 revenue was $98M; patient persistence, dose mix and unique new users remain undisclosed.
- What would move the thesis
- Review Q3 product revenue and any same-period dose/channel information. Company-wide volume or price cannot substitute for the pill’s figures; growth alone does not prove access expansion.
- Next checkpoint
- Confirmed Lilly Q3 results: October 29, 2026
Source record ↗UNDER OBSERVATION
Oral Wegovy access
- Starting evidence
- Novo reports high cash-led prescription volume; 9 mg and 25 mg combined is not the maintenance-dose share.
- What would move the thesis
- Review pill sales, script period, dose distribution and channel capture. Record naive-user claims with their lookback; do not infer incremental users from manufacturer shipments.
- Next checkpoint
- Novo nine-month report: November 4, 2026
Source record ↗UNDER OBSERVATION
Maintenance-year affordability
- Starting evidence
- 2026 Foundayo offers include expiry, caps and refill rules. Household all-in cost and payer net cost are not measured.
- What would move the thesis
- Record 2027 cash/card terms by dose, 45-day conditions, visit and membership fees. Keep the January Wegovy list-price change distinct from household and rebate-net costs.
- Next checkpoint
- 2026 offers expire December 31; review replacement terms
Source record ↗UNDER OBSERVATION
Generic quality-released supply
- Starting evidence
- Sevmia is approved for weight management but its 1 mg pen cannot supply the complete labeled course alone. Reviewed recalls named other diabetes products.
- What would move the thesis
- Track product/DIN/lot-specific approvals, recalls, released doses, actual shipments, coverage and paid fills. Keep Dr. Reddy’s restart target separate from confirmed supply; retain Canada, India and U.S. liraglutide branches.
- Next checkpoint
- Regulatory and shipment events; no fixed release date
Source record ↗UNDER OBSERVATION
Pill persistence and substitution
- Starting evidence
- No twelve-month launch cohort has matured at the baseline. Cash and insurance records are not fully linked.
- What would move the thesis
- Measure maintenance reach and six-/twelve-month persistence using the stated 60-day gap, source coverage and prior-drug history. Identify switches from injectables or compounded products; label insured-only slices.
- Next checkpoint
- Earliest launch-cohort anniversaries January/April 2027, plus data lag
Source record ↗UNDER OBSERVATION
Medicare Bridge and other coverage
- Starting evidence
- CMS provides eligible users a $50 copay through December 2027; utilization is not published in the reviewed record.
- What would move the thesis
- Seek unique beneficiaries, prior-authorization requests and final decisions, prior use, persistence and spending if CMS publishes them. Track commercial and Medicaid changes separately; nonfill is not automatically denial.
- Next checkpoint
- Bridge cohort anniversary from July 2027; program end December 31, 2027
Source record ↗These are monitoring questions, not completed outcomes. Company targets retain that label; unscheduled disclosures have no invented deadline. Later observations must carry their own date, source and measurement scope.
Record linkagePublication 1001 · Thematic tracker 7. Later observations and judgments remain separate from this starting record.